Aldeyra Therapeutics Inc
Research Aldeyra Therapeutics Inc (ALDX) on Bullrun: market cap USD 93.50M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALDX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 93.50M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 5.45M
- Free cash flow-USD 4.61M
Valuation Snapshot
latest market cap is USD 93.50M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 33.85M | -USD 33.35M | n/a | -0.56 | USD 70.04M | USD 15.25M | USD 44.25M |
| FY2024 | USD 0 | -USD 55.85M | -USD 43.21M | n/a | -0.94 | USD 54.53M | USD 15.03M | USD 71.00M |
| FY2023 | n/a | -USD 37.54M | -USD 30.33M | n/a | -0.64 | USD 142.82M | USD 15.15M | USD 119.80M |
| FY2022 | n/a | -USD 62.02M | -USD 56.65M | n/a | -1.06 | USD 144.42M | USD 15.83M | USD 151.01M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 93.50M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 311.64M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 297.65M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 206.47M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 407.58M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 232.32M | n/a | n/a | n/a |
About Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aldeyra Therapeutics Inc's market cap?
Aldeyra Therapeutics Inc's market capitalization is USD 93.50M.
What does Aldeyra Therapeutics Inc do?
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.